The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Open accessAbstract
Summary: Investigators developed chimeric antigen receptors (CAR s) for expression on T cells more than 25 years ago. When the CAR is derived from an antibody, the resultant cell should combine the desirable targeting features of an antibody (e.g. lack of requirement for major histocompatibility complex recognition, ability to recognize non‐protein antigens) with the persistence, trafficking, and effector functions of a T cell. This article describes how the past two decades have seen a crescendo of research which has now begun to translate these potential benefits into effective treatments for patients with cancer. We describe the basic design of CAR s, describe how antigenic targets are selected, and the initial clinical experience with CAR‐T cells. Our review then describes our own and other investigators' work aimed at improving the function of CAR s and reviews the clinical studies in hematological and solid malignancies that are beginning to exploit these approaches. Finally, we show the value of adding additional engineering features to CAR‐T cells, irrespective of their target, to render them better suited to function in the tumor environment, and discuss how the safety of these heavily modified cells may be maintained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“This combination does, however, have the potential for uncontrolled proliferation and activation of the CAR-T cells (179) and will need to be examined using careful dose escalation studies and – ideally – with other safety interventions in place (see ‘Increasing the safety of CAR-T cells’).”
BackgroundRosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1477 · Cited by 1,765
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Self-citationKochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Self-citationThe biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Self-citationRooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D.-K., Bowman, L. C., Krance, R. A., Brenner, M. K., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1549 · Cited by 1,135
Self-citationHuman T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Self-citationLamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Memory T Cell Subsets, Migration Patterns, and Tissue Residence
Mueller, S. N., Gebhardt, T., Carbone, F. R., & Heath, W. R. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095954 · Cited by 839
Irving, B. A., & Weiss, A. (1991) · Cell · doi:10.1016/0092-8674(91)90314-o · Cited by 805
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Self-citationCellular responses to viral infection in humans: lessons from Epstein–Barr virus
Hislop, A. D., Taylor, G. S., Sauce, D., & Rickinson, A. B. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141553 · Cited by 766
An inducible caspase 9 safety switch for T-cell therapy
Straathof, K. C., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 742
Self-citationTill, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 722
Human cytomegalovirus infection and expression in human malignant glioma.
Cobbs, C., Harkins, L. E., Samanta, M., Gillespie, G. Y., Bharara, S., King, P. H., Nabors, B., Cobbs, C. G., & Britt, W. J. (2002) · PubMed · Cited by 717
Lamers, C. H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 704
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
Cancer associated fibroblasts: the dark side of the coin.
Cirri, P., & Chiarugi, P. (2011) · Europe PMC (PubMed Central) · Cited by 654
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Paths to stemness: building the ultimate antitumour T cell
Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3322 · Cited by 599
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Maus, M. V., Haas, A. R., Beatty, G. L., Albelda, S. M., Levine, B. L., Liu, X., Zhao, Y., Kalos, M., & June, C. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0006 · Cited by 586
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 577
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Self-citationIL-2, Regulatory T Cells, and Tolerance
Nelson, B. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.3983 · Cited by 556
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Moon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Self-citationTill, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Jensen, M. C., Popplewell, L., Cooper, L. J., DiGiusto, D., Kalos, M., Ostberg, J. R., & Forman, S. J. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.014 · Cited by 529
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Self-citationWilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
Sportès, C., Hakim, F. T., Memon, S. A., Zhang, H., Chua, K. S., Brown, M. R., Fleisher, T. A., Krumlauf, M. C., Babb, R. R., Chow, C. K., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071681 · Cited by 476
Understanding the generation and function of memory T cell subsets
Lanzavecchia, A., & Sallusto, F. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.04.010 · Cited by 462
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458
Self-citationT cell receptor signalling networks: branched, diversified and bounded
Brownlie, R. J., & Zamoyska, R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3403 · Cited by 453
Zhao, Y., Moon, E., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 450
Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 443
Immune resistance orchestrated by the tumor microenvironment
Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., & Kurosawa, Y. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90502-x · Cited by 429
Mitchell, D. A., Xie, W., Schmittling, R., Learn, C., Friedman, A., McLendon, R. E., & Sampson, J. H. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-035 · Cited by 388
Ahmed, N., Salsman, V. S., Kew, Y., Shaffer, D., Powell, S., Zhang, Y. J., Grossman, R. G., Heslop, H. E., & Gottschalk, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1322 · Cited by 384
Self-citationJekyll and Hyde: the role of the microenvironment on the progression of cancer
Allen, M., & Louise Jones, J. (2011) · The Journal of Pathology · doi:10.1002/path.2803 · Cited by 375
Kahlon, K. S., Brown, C., Cooper, L. J. N., Raubitschek, A., Forman, S. J., & Jensen, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0454 · Cited by 368
Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma
Yaghoubi, S. S., Jensen, M. C., Satyamurthy, N., Budhiraja, S., Paik, D., Czernin, J., & Gambhir, S. S. (2009) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1278 · Cited by 366
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
Song, D.-G., Ye, Q., Poussin, M., Harms, G. M., Figini, M., & Powell, D. J. (2012) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 355
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor-Papadimitriou, J., Burchell, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4901 · Cited by 346
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Kakarla, S., Chow, K. K., Mata, M., Shaffer, D. R., Song, X.-T., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.110 · Cited by 346
Self-citationLanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Urbanska, K., Lanitis, E., Poussin, M., Lynn, R. C., Gavin, B. P., Kelderman, S., Yu, J., Scholler, N., & Powell, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3890 · Cited by 322
Guest, R. D., Hawkins, R. E., Kirillova, N., Cheadle, E. J., Arnold, J., O'Neill, A., Irlam, J., Chester, K. A., Kemshead, J. T., Shaw, D. M., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000161397.96582.59 · Cited by 318
Bollard, C. M., Rössig, C., Calonge, M. J., Huls, M. H., Wagner, H.-J., Massague, J., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2002) · Blood · doi:10.1182/blood.v99.9.3179 · Cited by 316
Self-citationIL-15 and IL-2: a matter of life and death for T cells in vivo
Li, X. C., Demirci, G., Ferrari-Lacraz, S., Groves, C., Coyle, A., Malek, T. R., & Strom, T. B. (2001) · Nature Medicine · doi:10.1038/83253 · Cited by 312
Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K. D., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 311
Stephan, M. T., Ponomarev, V., Brentjens, R. J., Chang, A. H., Dobrenkov, K. V., Heller, G., & Sadelain, M. (2007) · Nature Medicine · doi:10.1038/nm1676 · Cited by 299
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31827806e6 · Cited by 277
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
Vera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., Wu, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017061 · Cited by 275
Self-citationIn vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu, P., Yang, J. C.-H., Cowherd, R., Treisman, J. S., Shafer, G., Eshhar, Z., & Rosenberg, S. A. (1995) · PubMed · Cited by 273
Gottschalk, S., Ng, C. Y. C., Perez, M., Smith, C. A., Sample, C., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2001) · Blood · doi:10.1182/blood.v97.4.835 · Cited by 271
Self-citationBridgeman, J. S., Hawkins, R. E., Bagley, S., Blaylock, M., Holland, M., & Gilham, D. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901766 · Cited by 267
Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P., & Abken, H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7647 · Cited by 260
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Tamada, K., Geng, D., Sakoda, Y., Bansal, N., Srivastava, R., Li, Z., & Davila, E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1449 · Cited by 259
Hwu, P., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A., & Eshhar, Z. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.1.361 · Cited by 256
IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis
Carrette, F., & Surh, C. D. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.04.010 · Cited by 254
Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43490 · Cited by 253
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
Curran, K. J., Pegram, H. J., & Brentjens, R. J. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2604 · Cited by 251
Cooper, L. J. N., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1989 · Cited by 248
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Chow, K. K., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., Rainusso, N., Wu, M.-F., Liu, H., Kew, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.210 · Cited by 245
Self-citationDetection of human cytomegalovirus in different histological types of gliomas
Scheurer, M. E., Bondy, M. L., Aldape, K. D., Albrecht, T., & El-Zein, R. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0359-1 · Cited by 244
Gong, M. C., Latouche, J.-B., Krause, A., Heston, W. D. W., Bander, N. H., & Sadelain, M. (1999) · Neoplasia · doi:10.1038/sj.neo.7900018 · Cited by 241
Improving T Cell Therapy for Cancer
Leen, A. M., Rooney, C. M., & Foster, A. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141527 · Cited by 240
Savoldo, B., Rooney, C. M., Di Stasi, A., Abken, H., Hombach, A., Foster, A. E., Zhang, L., Heslop, H. E., Brenner, M. K., & Dotti, G. (2007) · Blood · doi:10.1182/blood-2006-11-059139 · Cited by 234
Self-citationTrans-presentation: A novel mechanism regulating IL-15 delivery and responses
Stonier, S. W., & Schluns, K. S. (2010) · Immunology Letters · doi:10.1016/j.imlet.2009.09.009 · Cited by 226
Brown, C. E., Starr, R., Aguilar, B., Shami, A. F., Martinez, C., D'Apuzzo, M., Barish, M. E., Forman, S. J., & Jensen, M. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1669 · Cited by 225
Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells
Barrett, D. M., Zhao, Y., Liu, X., Jiang, S., Carpenito, C., Kalos, M., Carroll, R. G., June, C. H., & Grupp, S. A. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.070 · Cited by 220
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Stancovski, I., Schindler, D. G., Waks, T., Yarden, Y., Sela, M., & Eshhar, Z. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.11.6577 · Cited by 216
Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215
Self-citationWang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C. G., Till, B., Raubitschek, A., Forman, S. J., Qian, X., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.028 · Cited by 213
Tettamanti, S., Marin, V., Pizzitola, I., Magnani, C. F., Giordano Attianese, G. M. P., Cribioli, E., Maltese, F., Galimberti, S., Lopez, A. F., Biondi, A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12282 · Cited by 211
Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor
Foster, A. E., Dotti, G., Lu, A., Khalil, M., Brenner, M. K., Heslop, H. E., Rooney, C. M., & Bollard, C. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177092b · Cited by 210
Self-citationCytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Moritz, D., Wels, W., Mattern, J., & Groner, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4318 · Cited by 208
Regulation of Antitumor Immune Responses by the IL‐12 Family Cytokines, IL‐12, IL‐23, and IL‐27
Xu, M., Mizoguchi, I., Morishima, N., Chiba, Y., Mizuguchi, J., & Yoshimoto, T. (2010) · Journal of Immunology Research · doi:10.1155/2010/832454 · Cited by 203
Rossig, C., Bollard, C. M., Nuchtern, J. G., Rooney, C. M., & Brenner, M. K. (2002) · Blood · doi:10.1182/blood.v99.6.2009 · Cited by 201
Self-citationTerakura, S., Yamamoto, T. N., Gardner, R. A., Turtle, C. J., Jensen, M. C., & Riddell, S. R. (2012) · Blood · doi:10.1182/blood-2011-07-366419 · Cited by 196
Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells
Ahmed, N., Ratnayake, M., Savoldo, B., Perlaky, L., Dotti, G., Wels, W. S., Bhattacharjee, M. B., Gilbertson, R. J., Shine, H. D., Weiss, H. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4309 · Cited by 192
Self-citationWilkie, S., Burbridge, S. E., Chiapero-Stanke, L., Pereira, A. C. P., Cleary, S., van der Stegen, S. J. C., Spicer, J. F., Davies, D. M., & Maher, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127951 · Cited by 189
Lanitis, E., Poussin, M., Hagemann, I. S., Coukos, G., Sandaltzopoulos, R., Scholler, N., & Powell, D. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.256 · Cited by 187
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy
Ramos, C. A., & Dotti, G. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.573476 · Cited by 182
Self-citationT Cell Affinity Regulates Asymmetric Division, Effector Cell Differentiation, and Tissue Pathology
King, C. G., Koehli, S., Hausmann, B., Schmaler, M., Zehn, D., & Palmer, E. (2012) · Immunity · doi:10.1016/j.immuni.2012.06.021 · Cited by 172
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., & Bigner, D. D. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.04.001 · Cited by 172
T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies
Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K. H., Kakarla, S., Spencer, D. M., Dotti, G., Wu, M.-F., Liu, H., Kenney, S., et al. (2011) · Blood · doi:10.1182/blood-2010-04-278218 · Cited by 167
Self-citationQuintarelli, C., Vera, J., Savoldo, B., Giordano-Attianese, G., Pule, M., Foster, A., Heslop, H., Rooney, C., Brenner, M., & Dotti, G. (2007) · Blood · doi:10.1182/blood-2007-02-072843 · Cited by 164
Self-citationRossig, C., Bollard, C. M., Nuchtern, J. G., Merchant, D. A., & Brenner, M. K. (2001) · International Journal of Cancer · doi:10.1002/ijc.1457 · Cited by 161
Self-citationChimeric NK-receptor–bearing T cells mediate antitumor immunotherapy
Zhang, T., Lemoi, B. A., & Sentman, C. L. (2005) · Blood · doi:10.1182/blood-2004-11-4365 · Cited by 157
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 157
TGFβ signaling in health and disease
Akhurst, R. J. (2004) · Nature Genetics · doi:10.1038/ng0804-790 · Cited by 154
Westwood, J. A., Smyth, M. J., Teng, M. W. L., Moeller, M., Trapani, J. A., Scott, A. M., Smyth, F. E., Cartwright, G. A., Power, B. E., Hönemann, D., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504312102 · Cited by 148
Haynes, N. M., Snook, M. B., Trapani, J. A., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.182 · Cited by 139
Nakazawa, Y., Huye, L. E., Salsman, V. S., Leen, A. M., Ahmed, N. M., Rollins, L. A., Dotti, G., Gottschalk, S. M., Wilson, M. H., & Rooney, C. M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.131 · Cited by 138
Self-citationKong, S., Sengupta, S., Tyler, B., Bais, A. J., Ma, Q., Doucette, S., Zhou, J., Sahin, A., Carter, B. S., Brem, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0319 · Cited by 134
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis
Dotti, G., Savoldo, B., Pulè, M. A., Straathof, K. C. M., Biagi, E., Yvon, E. S., Vigouroux, S., Brenner, M. K., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-08-3337 · Cited by 128
Self-citationHuang, G., Yu, L., Cooper, L. J. N., Hollomon, M., Huls, H., & Kleinerman, E. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2778 · Cited by 127
Niederman, T. M. J., Ghogawala, Z., Carter, B. S., Tompkins, H. S., Russell, M. M., & Mulligan, R. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092562399 · Cited by 125
Spear, P., Barber, A., Rynda‐Apple, A., & Sentman, C. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103019 · Cited by 119
Peinert, S., Prince, H. M., Guru, P., Kershaw, M. H., Smyth, M. J., Trapani, J. A., Gambell, P. C., Harrison, S. J., Scott, A. M., Smyth, F. E., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.21 · Cited by 118
Dual-specific T cells combine proliferation and antitumor activity
Kershaw, M. H., Westwood, J. A., & Hwu, P. (2002) · Nature Biotechnology · doi:10.1038/nbt756 · Cited by 114
Lehner, M., Götz, G., Proff, J., Schaft, N., Dörrie, J., Full, F., Ensser, A., Muller, Y. A., Cerwenka, A., Abken, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031210 · Cited by 111
Genetic instability: tipping the balance
Janssen, A., & Medema, R. H. (2012) · Oncogene · doi:10.1038/onc.2012.576 · Cited by 111
Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells
Davies, D. M., Foster, J., van der Stegen, S. J. C., Parente‐Pereira, A. C., Chiapero-Stanke, L., Delinasios, G. J., Burbridge, S. E., Kao, V., Liu, Z., Bosshard‐Carter, L., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00493 · Cited by 110
Cooper, L. J. N., Al-Kadhimi, Z. S., Serrano, L. M., Pfeiffer, T., Olivares, S., Castro, A., Chang, W.-C., Gonzalez, S., Smith, D. D., Forman, S. J., et al. (2004) · Blood · doi:10.1182/blood-2004-03-1208 · Cited by 109
Song, D.-G., Ye, Q., Santoro, S. P., Fang, C., Best, A. J., & Powell, D. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.143 · Cited by 108
Hombach, A. A., Schildgen, V., Heuser, C., Finnern, R., Gilham, D. E., & Abken, H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4650 · Cited by 106
Cancer-Associated Fibroblasts as Targets for Immunotherapy
Kakarla, S., Song, X., & Gottschalk, S. M. (2012) · Immunotherapy · doi:10.2217/imt.12.112 · Cited by 106
Self-citationEvaluating risks of insertional mutagenesis by DNA transposons in gene therapy
Hackett, P. B., Largaespada, D. A., Switzer, K. C., & Cooper, L. J. N. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.005 · Cited by 104
Morgenroth, A., Cartellieri, M., Schmitz, M., Günes, S., Weigle, B., Bachmann, M. P., Abken, H., Rieber, E. P., & Temme, A. (2007) · The Prostate · doi:10.1002/pros.20608 · Cited by 104
Gene therapy for primary immunodeficiencies: part 1
Cavazzana, M., Fischer, A., Hacein‐Bey‐Abina, S., & Aiuti, A. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.008 · Cited by 103
Anti-Tumor Activity of Human T Cells Expressing the CC49-zeta Chimeric Immune Receptor
MCGUINNESS, R. P., Ge, Y. C., Patel, S. D., et al. (1999) · Human Gene Therapy · doi:10.1089/10430349950018968 · Cited by 100
Jensen, M. C., Tan, G., Forman, S. J., Wu, A. M., & Raubitschek, A. A. (1998) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.1998.v4.pm9763110 · Cited by 100
Nolan, K. F., Yun, C. O., Akamatsu, Y., et al. (1999) · PubMed · Cited by 99
Hombach, A. A., Heuser-Loy, C., Sircar, R., Tillmann, T., Diehl, V., Pohl, C., & Abken, H. (1998) · PubMed · Cited by 97
Peripheral tissue surveillance and residency by memory T cells
Gebhardt, T., Mueller, S. N., Heath, W. R., & Carbone, F. R. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.08.008 · Cited by 92
Burns, W. R., Zhao, Y., Frankel, T. L., Hinrichs, C. S., Zheng, Z., Xu, H., Feldman, S. A., Ferrone, S., Rosenberg, S. A., & Morgan, R. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2824 · Cited by 89
Wang, J., Press, O. W., Lindgren, C. G., Greenberg, P. D., Riddell, S. R., Qian, X., Laugen, C., Raubitschek, A. A., Forman, S. J., & Jensen, M. C. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.011 · Cited by 81
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
Pinthus, J. H., Waks, T., Malina, V., Kaufman‐Francis, K., Harmelin, A., Aizenberg, I., Kanety, H., Ramon, J., & Eshhar, Z. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22284 · Cited by 79
All in the Stroma: Cancer's Cosa Nostra
Marx, J. L. (2008) · Science · doi:10.1126/science.320.5872.38 · Cited by 78
Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myeloma
Barber, A., Zhang, T., Megli, C., Wu, J., Meehan, K. R., & Sentman, C. L. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.04.010 · Cited by 78
Altenschmidt, U., Kahl, R., Moritz, D. R., Schnierle, B. S., Gerstmayer, B., Wels, W. S., & Groner, B. (1996) · PubMed · Cited by 77
Sharifzadeh, Z., Rahbarizadeh, F., Shokrgozar, M. A., Ahmadvand, D., Mahboudi, F., Jamnani, F. R., & Moghimi, S. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.010 · Cited by 76
Wagner, H., Bollard, C. M., Vigouroux, S., Huls, M. H., Anderson, R. W., Prentice, H. G., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700664 · Cited by 76
Self-citationWillemsen, R., Debets, R., Hart, E., Hoogenboom, H. R., Bolhuis, R., & Chames, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301570 · Cited by 76
Transiently redirected T cells for adoptive transfer
Almåsbak, H., Rian, E., Hoel, H. J., Pulè, M. A., Wälchli, S., Kvalheim, G., Gaudernack, G., & Rasmussen, A. (2010) · Cytotherapy · doi:10.3109/14653249.2010.542461 · Cited by 73
Perna, S. K., Angelis, B. D., Pagliara, D., Hasan, S. T., Zhang, L., Mahendravada, A., Heslop, H. E., Brenner, M. K., Rooney, C. M., Dotti, G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2143 · Cited by 72
Self-citationT Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory Mechanisms
Sun, J., Dotti, G., Huye, L. E., Foster, A. E., Savoldo, B., Gramatges, M. M., Spencer, D. M., & Rooney, C. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.185 · Cited by 69
Self-citationGeneration of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma
Ghazi, A., Ashoori, A., Hanley, P. J., Brawley, V. S., Shaffer, D. R., Kew, Y., Powell, S. Z.-E., Grossman, R. G., Grada, Z., Scheurer, M. E., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318247642f · Cited by 69
Self-citationWillemsen, R. A., Ronteltap, C. P. M., Chames, P., Debets, R., & Bolhuis, R. L. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7853 · Cited by 67
Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas
Kerkar, S. P., Leonardi, A. J., van Panhuys, N., Zhang, L., Yu, Z., Crompton, J. G., Pan, J. H., Palmer, D. C., Morgan, R. A., Rosenberg, S. A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.58 · Cited by 67
Genetically engineered T cells to target EGFRvIII expressing glioblastoma
Bullain, S., Sahin, A., Szentirmai, O., Sanchez, C., Lin, N., Baratta, E., Waterman, P. R., Weissleder, R., Mulligan, R. C., & Carter, B. S. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9889-1 · Cited by 67
Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells
Maher, J. (2012) · ISRN Oncology · doi:10.5402/2012/278093 · Cited by 67
Gilham, D. E., O'Neil, A., Hughes, C., Guest, R. D., Kirillova, N., Lehane, M., & Hawkins, R. E. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00002 · Cited by 67
Ocvirk, J., Heeger, S., McCloud, P., & Hofheinz, R. (2013) · Radiology and Oncology · doi:10.2478/raon-2013-0014 · Cited by 63
Schuberth, P., Jakka, G., Jensen, S. M., Wadle, A., Gautschi, F., Haley, D. P., Haile, S. R., Mischo, A., Held, G., Thiel, M., et al. (2012) · Gene Therapy · doi:10.1038/gt.2012.48 · Cited by 61
Engineered T cells for pancreatic cancer treatment
Katari, U. L., Keirnan, J. M., Worth, A. C., Hodges, S. E., Leen, A. M., Fisher, W. E., & Vera, J. F. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00344.x · Cited by 61
Perret, R., & Ronchese, F. (2008) · Tissue Antigens · doi:10.1111/j.1399-0039.2008.01088.x · Cited by 59
Bear, A. S., Morgan, R. A., Cornetta, K., June, C. H., Binder-Scholl, G., Dudley, M. E., Feldman, S. A., Rosenberg, S. A., Shurtleff, S. A., Rooney, C. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.288 · Cited by 59
Self-citationRecognition of human colon cancer by T cells transduced with a chimeric receptor gene
Daly, T., Royal, R. E., Kershaw, M. H., Treisman, J. S., Wang, G., Li, W., Herlyn, D., Eshhar, Z., & Hwu, P. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700121 · Cited by 54
Gattenlöhner, S., Marx, A., Markfort, B., Pscherer, S., Landmeier, S., Juergens, H., Müller–Hermelink, H., Matthews, I., Beeson, D., Vincent, A. C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0542 · Cited by 50
Meier, R., Golovko, D. M., Tavri, S., Henning, T. D., Knopp, C., Piontek, G., Rudelius, M., Heinrich, P., Wels, W. S., & Daldrup-Link, H. E. (2010) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22652 · Cited by 45
Xu, X., Zhao, H., & Tang, Y. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.715350 · Cited by 42
Efficacy of IL‐2‐ versus IL‐15‐stimulated CD8 T cells in adoptive immunotherapy
Mueller, K., Schweier, O., & Pircher, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200838426 · Cited by 42
Interleukin-15 in Gene Therapy of Cancer
Ochoa, M. C., Mazzolini, G. D., Hervás‐Stubbs, S., Sanmamed, M. F., Berraondo, P., & Melero, I. (2012) · Current Gene Therapy · doi:10.2174/156652313804806561 · Cited by 39
Ren‐Heidenreich, L., Mordini, R., Hayman, T. J., Siebenlist, R. E., & LeFever, A. V. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0301-7 · Cited by 32
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals
Arber, C., Abhyankar, H. A., Heslop, H., Brenner, M. K., Liu, H., Dotti, G., & Savoldo, B. (2013) · Gene Therapy · doi:10.1038/gt.2013.25 · Cited by 31
Self-citationCheung, N. V., Guo, H.-F., Modak, S. I., & Cheung, I. Y. (2003) · Hybridoma and Hybridomics · doi:10.1089/153685903322328938 · Cited by 26
Ahmed, N. M., Brawley, V. S., Diouf, O., Anderson, P. M., Hicks, J. M., Wang, L. E., Dotti, G., Wels, W. S., Liu, H., Gee, A. P., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-3500 · Cited by 8
Self-citation
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Self-citation
Metadata
- Authors
- Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2013-12-13
- Volume
- 257
- Issue
- 1
- Pages
- 107-126
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W1977949161
- Cited by
- 508
- References
- 189
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.